New Corporate Office
We are proud to announce our new corporate office located in Saddle Brook, NJ
Blinded Diagnostics LLC
Park 80 West - 250 Pehle Avenue - Suite 200
Saddle Brook, NJ 07663-5836
e:
info@blindeddiagnostics.com t: +1 (201) 291-2822
f: +1 (201) 689-9182
Blinded Diagnostics Appoints Jon Klippel as VP, Business Development
Saddle Brook, NJ, July 13, 2012: Blinded Diagnostics today announced the expansion of their business development efforts
by appointing Jon Klippel as the new Vice President of Business Development. Jon, a 25 year veteran of the medical device
and diagnostics industry, will be working from the Saddle Brook office to provide point of care diagnostics solutions to
pharmaceutical and biopharmaceutical clients.
"With the addition of Jon Klippel to the team, we plan to expand our reach to many more pharmaceutical companies interested
in same day lab test results using point of care diagnostics" said Steve Karuppan, CEO of Blinded Diagnostics. He added
that "Jon's experience is an excellent fit because he has first-hand knowledge of the challenges of providing pharmaceutical
companies with practical cost saving services."
Prior to joining Blinded Diagnostics, Jon had responsibility for a range of business development activities at Cegedim Relationship
Management, a Life Sciences CRM service provider located in NJ. His medical device background includes both sales and marketing
management for wound care products as well as market development for a point-of-care instrument to assist in the early detection of
melanoma. Additionally, a large portion of Jon's career was spent in marketing with Howmedica, the former orthopedic division of Pfizer.
About Blinded Diagnostics
A pioneering contract service organization specializing in sourcing and supporting point of care diagnostic test platforms that
provide same day lab test results for pharmaceutical clinical trials. Blinded Diagnostics has a successful track record of expertise
in meeting large pharmaceutical company testing needs with thorough knowledge of the protocol design, Investigator training
and firmware encryption. As an innovator with partners in point-of-care diagnostics, Blinded Diagnostics is at the forefront of a
paradigm shift that brings flexibility and efficiency for trial sponsors.
Blinded Diagnostics Names Paul S. Savuto as President and CFO
SADDLE BROOK, N.J., June 8, 2011 PRNewswire - Blinded Diagnostics LLC, has named Paul S. Savuto to the senior
management position of President and Chief Financial Officer. Paul was formerly Director of Market Development
and Alternate Site for International Technidyne Corporation (ITC),
"Paul brings exceptional creativity and innovation as well as a track record of success in the point-of-care industry.
He possesses an extensive knowledge of the application of new diagnostic technology in pharmaceutical clinical
trials." said Steven Karuppan, Chief Executive Officer of Blinded Diagnostics. "We look forward to seeing the
company progress under his leadership."
Mr. Savuto has been a sales and marketing executive in the medical device and diagnostic industry for the past
25 years. His industry experience includes development and product launch of over 40 new medical devices for
Baxter, Vickers Medical, WR Grace (NMC), Medtronic, PDI and ITC.
Paul holds a Bachelor's degree in Microbiology from the University of Maine at Orono, a Master's degree in
Clinical Microbiology from Columbia University (College of Physicians and Surgeons) and a Masters of Business
Administration in Marketing from Pace University (Lubin School of Business).
About Blinded Diagnostics
A pioneering contract service organization specializing in sourcing and supporting point-of-care test solutions
for pharmaceutical clinical trials, Blinded Diagnostics has a successful track record of expertise in meeting
pharmaceutical company testing needs with thorough knowledge of the protocol design, Investigator training
and firmware encryption. As an innovator with partners in point-of-care diagnostics, Blinded Diagnostics is at the
forefront of a paradigm shift that brings flexibility and efficiency for trial sponsors.
Blinded Diagnostics Appoints Patty Averette as VP, Business Development
Blinded Diagnostics today announced the expansion of their business development efforts by appointing Patricia H. Averette as the new
Vice President of Business Development. Patty, a seasoned health care professional with a solid background in Hematology Lab Diagnostics,
Technical Service and Sales, will be working from Charlotte, North Carolina to provide point of care diagnostics solutions to pharmaceutical
and biopharmaceutical clients in the Southeastern US.
"We are glad to add Patty to the team, she will be introducing our services to the Research Triangle Park area and Southeastern biotech
companies interested in same day lab test results for clinical trials" said Steve Karuppan, CEO of Blinded Diagnostics. He added that
"Patty's experience is a plus for Blinded Diagnostics because she has first-hand knowledge
in point of care diagnostics solutions."
Patty has a successful track record in Strategic Sales and Business Development focusing on innovative and disruptive technologies. She
has held management roles in Technical Service, Clinical Informatics, along with Product Management and Technical Sales with Abbott
Diagnostics, Inc. She achieved a BS in Medical Technology from the University of North Carolina, Greensboro and served as the Assistant
Supervisor of Hematology at the Carolinas Medical Center in Charlotte, NC. Her Medical Device experience includes Point-of-Care testing
and EMR experience. She brings a strong knowledge of GMP and regulatory practices in all scientific disciplines.
About Blinded Diagnostics
A pioneering contract service organization specializing in sourcing and supporting point of care diagnostic test platforms that
provide same day lab test results for pharmaceutical clinical trials. Blinded Diagnostics has a successful track record of expertise
in meeting large pharmaceutical company testing needs with thorough knowledge of the protocol design, Investigator training
and firmware encryption. As an innovator with partners in point-of-care diagnostics, Blinded Diagnostics is at the forefront of a
paradigm shift that brings flexibility and efficiency for trial sponsors.
Express Diagnostics Int'l, Inc. Appoints Blinded Diagnostics to offer Drugs of Abuse
and Alcohol Testing for use in Pharmaceutical Clinical Trials
Blinded Diagnostics today announced the expansion of their diagnostic product portfolio with the addition of an extensive line of
screening tests for drugs of abuse and alcohol from Express Diagnostics Int'l, Inc. (EDI) of Blue Earth, MN. The partnership will
focus on offering easy to use, CLIA-Waived and affordable point of care diagnostic tools for patient enrollment in pharmaceutical
and biopharmaceutical clinical trials for same-day lab test results.
"With the ability to customize the configurations of twenty-two (22) different screening tests, our clients can get exactly what the
clinical trial protocol requires for exclusion criteria," said Steve Karuppan, CEO of Blinded Diagnostics. He added, "We are also
looking forward to the US launch of the AnemiaCheck TM POC Quantitative Hematocrit Test, as it will certainly have great utility for
our clients' projects."
In October 2012, AnemiaCheck™ POC Quantitative Hematocrit Test was selected as a top 10 finalist for the LifeScience Alley New
Technology Showcase. AnemiaCheck™, from IntraMed Diagnostics, a subsidiary of EDI, is an entirely self-contained, disposable device
designed to separate red blood cells from plasma using specialized filtering materials. This innovative new product is CE marked but
is not currently available in the US.
Rich Strasser, COO of Express Diagnostics said, "Blinded Diagnostics is in an excellent position to reach the global clinical trial
market and provide the support for customized testing solutions along with product training."
About Express Diagnostics Int'l, Inc.
Express Diagnostics Int'l (EDI), manufactures and distributes the AnemiaCheck™ POC Quantitative Hematocrit Test, a rapid point-of-care
device for anemia screening. AnemiaCheck™ delivers quantitative hematocrit results in 15 minutes without instrumentation.
Additionally, EDI manufactures and distributes DrugCheck® onsite urine, breath, and saliva screening devices. With accuracy comparable
to laboratory testing, DrugCheck® onsite devices provide a variety of industries fast, cost-effective alternatives to higher-priced lab
services. Sold through a worldwide distributor network since 2002, DrugCheck® continues to build on its consistent growth in the on-site
drug testing industry. www.drugcheck.com.
Spaulding Clinical Research Announces Collaboration with Blinded Diagnostics for Centralized
Cardiac Safety Services for Select Pharmaceutical Clients
Spaulding Clinical Research has agreed to offer ECG services using the new Spaulding webECG™ Diagnostic ECG Management system for late
stage clinical trials through Blinded Diagnostics. This web-based solution includes the Spaulding Model 1000iQ, a hand-held diagnostic
12-lead electrocardiograph designed to provide an easy-to-use, cost-effective, diagnostic assessment, while centralizing all data on a
web-based system that allows for immediate access to study data globally. The multi-year collaboration assigns Blinded Diagnostics as a
business development resource for a select group of pharmaceutical companies.
"We are very pleased with the relationship that we have built with Blinded Diagnostics. They are a knowledgeable and professional
organization and will represent Spaulding's unique service offerings well. We are confident in their ability to deliver customer-focused
solutions to this select group of pharmaceutical companies," states Kevin Geno, VP of Sales and Marketing for Spaulding Clinical Research.
"The Spaulding Model 1000iQ Electrocardiograph is an innovative and effective point of care 12-lead ECG device for use in clinical trials..."
states Steve Karuppan, CEO of Blinded Diagnostics, "and we are particularly impressed by the Spaulding webECG data storage capability,
analysis solutions and connectivity features for use in centralizing cardiac safety data from phase II-IV global trials."
About Spaulding Clinical Research, LLC
Spaulding Clinical Research, LLC (www.spauldingclinical.com) provides Clinical Pharmacology, Cardiac Core Lab clinical research services,
and is a medical device manufacturer. Spaulding Clinical operates a 155-bed clinical pharmacology unit with 96-beds of telemetry in West
Bend, Wisconsin, USA. The facility is paperless, with a Phase I Electronic Data Capture system and bidirectional interfaces to safety lab,
bedside devices and telemetry. As a Phase I-IV Core ECG Laboratory provider, Spaulding Clinical offers the complete suite of equipment
provisioning and electrocardiograph over-reading services with state-of-the-art technologies, including the proprietary Spaulding Model
1000iQ Electrocardiograph, expertly-cardiologists and project managers.
